In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
BARDA reselects ICON as preferred partner
An article focused on the BARDA announcement that ICON continues to be a part of The Clinical Trials Planning and Execution component of the CSN, responsible for planning and executing clinical studies to support medical countermeasure development.
-
AI in Life Sciences – Covid pushes AI driven clinical trials and drug manufacturing into the limelight
ICON’s CIO, Tom Leary discusses the challenges to patient recruitment during the COVID pandemic and how big data, combined with advanced AI algorithms processing has the potential to reduce trial costs.
-
Listening to the patient for better outcomes
ICON’s Gretchen Goller discusses the importance of establishing and maintaining patient connection, and overcoming structural barriers with decentralised and hybrid trials. Read more in this PharmaVOICE article.
-
What clinical holds and pauses mean for COVID-19 countermeasure timelines
ICON’s Nuala Murphy and David Morse discuss trial pauses and clinical halts after three high-profile COVID-19 trials are temporarily halted as a result of potential safety issues being flagged by independent Data and Safety Monitoring Boards. Read more in this Biocentury article.
-
Pandemic priorities
The requirements for global HTA/reimbursement consideration have changed and are continuing to evolve in response to the current pandemic. This PharmaTimes article considers how drug sponsors can navigate a path to reimbursement success and market access for drugs that were in development prior to the pandemic.
-
Navigating cell therapy manufacturing amid pandemic woes
An article featuring expert commentary from ICON's Tamie Joeckel on supply-chain strategies to help mitigate vulnerabilities in both autologous and allogeneic cell therapy manufacturing.
-
Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan
This published study conducted by ICON's Health Economics team and Bristol-Myers Squibb evaluates a cost-effective new treatment for melanoma patients in Japan.
-
Planning a managed access programme: Advice for clinical teams
Managed access programmes (MAPs) are often unfamiliar territory for clinical teams, as their purpose and regulatory environment are very different from randomised controlled trials. ICON's Veronica Gutierrez Martinez considers how Sponsors need to plan carefully before undertaking a MAP so that they have the resources, processes, and tools in place to support the inevitable demand.
-
The impact of influenza vaccination on the COVID-19 pandemic? Evidence and lessons for public health policies
ICON's Richard Pitman joins global public health experts to address the importance of flu vaccination programs amid the COVID-19 pandemic.
-
How to measure your patient-centric impact
A patient insight article on the benefit of patient centric clinical trial design.
